Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
Pharmacology, Toxicology and Pharmaceutical Science
2
5%
Immunology and Microbiology
1
3%
Engineering
1
3%
Other
0
0%
Unknown
22
59%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 July 2021.
All research outputs
#9,515,597
of 27,789,359 outputs
Outputs from Gynecologic Oncology
#2,632
of 6,012 outputs
Outputs of similar age
#147,352
of 367,851 outputs
Outputs of similar age from Gynecologic Oncology
#36
of 81 outputs
Altmetric has tracked 27,789,359 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 6,012 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 367,851 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.